$0.81
2.78% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US48576U1060
Symbol
KPTI
Sector
Industry

Karyopharm Therapeutics, Inc. Stock price

$0.81
-0.02 2.77% 1M
-0.32 27.96% 6M
-0.05 5.90% YTD
+0.09 12.17% 1Y
-7.31 89.98% 3Y
-14.79 94.78% 5Y
-39.97 98.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.02 2.78%
ISIN
US48576U1060
Symbol
KPTI
Sector
Industry

Key metrics

Market capitalization $102.01m
Enterprise Value $162.71m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.10
P/S ratio (TTM) P/S ratio 0.69
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 1.77%
Revenue (TTM) Revenue $148.44m
EBIT (operating result TTM) EBIT $-125.97m
Free Cash Flow (TTM) Free Cash Flow $-120.46m
Cash position $133.56m
EPS (TTM) EPS $-1.14
P/E forward negative
P/S forward 0.69
EV/Sales forward 1.08
Short interest 14.40%
Show more

Is Karyopharm Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Karyopharm Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Karyopharm Therapeutics, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Karyopharm Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Karyopharm Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
148 148
2% 2%
100%
- Direct Costs 6.50 6.50
10% 10%
4%
142 142
1% 1%
96%
- Selling and Administrative Expenses 119 119
12% 12%
80%
- Research and Development Expense 149 149
15% 15%
100%
-126 -126
0% 0%
-85%
- Depreciation and Amortization 0.34 0.34
40% 40%
0%
EBIT (Operating Income) EBIT -126 -126
0% 0%
-85%
Net Profit -87 -87
37% 37%
-59%

In millions USD.

Don't miss a Thing! We will send you all news about Karyopharm Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Karyopharm Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
10 days ago
Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Elhan Webb - Senior Vice President, Investor Relations Richard Paulson - President and Chief Executive Officer Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - Chief Financial Officer Conference Call Participants Brian Abra...
Neutral
PRNewsWire
10 days ago
SHANGHAI and HONG KONG , Nov. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present the latest data from two clinical studies of selinexor in t...
Neutral
PRNewsWire
11 days ago
– Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out...
More Karyopharm Therapeutics, Inc. News

Company Profile

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Head office United States
CEO Richard Paulson
Employees 325
Founded 2008
Website www.karyopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today